After the second quarter of 2021 Roche Holding AG started describing its quarterly results as “good”: previously they had been “strong.” Over the following nine months, Roche’s stock price also weakened, falling by almost 13% against the NYSE Arca Pharmaceutical Index’s nearly 9% gain.
Stock Watch: Robust Diagnostics And Biosimilar Erosion Vie In Roche’s Q2
COVID-19 Testing May Support Roche Longer Than Expected
Roche’s stock price has underperformed in the last nine months in spite of a natural hedge on the strong US dollar that has troubled most other profitable pharma companies. Has Roche become a value stock?
More from Stock Watch
More from Business
• By
The US FDA approved anti-CD19 antibody Uplizna, from Amgen’s $27.8bn purchase of Horizon in 2023, for IgG4-related disease – a larger market than its original NMOSD indication.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.